Rocket Pharmaceuticals, Inc. (RCKT)

NGM – Цена в реальном времени. Валюта: USD

3.64

+0.05 (1.39%)

При закрытии: May 12, 2026, 4:00 PM EDT

3.65

+0.01 (0.27%)

После закрытия: May 12, 2026, 7:17 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Rocket Pharmaceuticals, Inc. (RCKT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Rocket Pharmaceuticals, Inc. (RCKT)

RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

Rocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 Transcript

Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI

Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder

Видео

No Data

Пресс-релизы

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Search stocks

Rocket Pharmaceuticals, Inc. (RCKT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Rocket Pharmaceuticals, Inc. (RCKT)

RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

Rocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 Transcript

Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI

Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder

Видео

No Data

Пресс-релизы

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress